IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
Go back to IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites| (NASDAQ: ICCM) | Delayed: 1.08 +0.03 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.05 | 52 Week High | $ | |||
| Open | $1.05 | 52 Week Low | $ | |||
| Day High | $1.12 | P/E | N/A | |||
| Day Low | $1.05 | EPS | $ | |||
| Volume | 92,753 | |||||



